MA51630A - Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancer - Google Patents
Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancerInfo
- Publication number
- MA51630A MA51630A MA051630A MA51630A MA51630A MA 51630 A MA51630 A MA 51630A MA 051630 A MA051630 A MA 051630A MA 51630 A MA51630 A MA 51630A MA 51630 A MA51630 A MA 51630A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- alone
- treatment
- combination
- immune checkpoint
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471875P | 2017-03-15 | 2017-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51630A true MA51630A (fr) | 2020-01-22 |
Family
ID=61913527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051630A MA51630A (fr) | 2017-03-15 | 2018-03-14 | Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancer |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200009204A1 (fr) |
EP (1) | EP3595690A1 (fr) |
JP (2) | JP2020510050A (fr) |
CN (1) | CN110461346A (fr) |
AU (2) | AU2018235944B2 (fr) |
CA (1) | CA3056392A1 (fr) |
MA (1) | MA51630A (fr) |
MX (1) | MX2019010797A (fr) |
WO (1) | WO2018170133A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2871910T3 (es) * | 2012-08-30 | 2021-11-02 | Amgen Inc | Un método para tratar el melanoma usando un virus de herpes simple y un inhibidor de puntos de control inmunitario |
AR112405A1 (es) * | 2017-08-07 | 2019-10-23 | Amgen Inc | Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas |
CN116870165A (zh) * | 2018-08-17 | 2023-10-13 | 北京奥源和力生物技术有限公司 | 用于治疗癌症的组合及其治疗用途 |
TW202214279A (zh) * | 2020-09-18 | 2022-04-16 | 大陸商成都美杰賽爾生物科技有限公司 | 溶瘤病毒與經改造的免疫細胞聯合治療腫瘤 |
EP4288140A1 (fr) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Traitement adjuvant du cancer |
WO2022252185A1 (fr) * | 2021-06-03 | 2022-12-08 | 上海允英生物医药科技有限公司 | Vecteur de virus oncolytique et son utilisation |
TW202321458A (zh) * | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
CN115463161A (zh) * | 2022-09-15 | 2022-12-13 | 广东天普生化医药股份有限公司 | 一种溶瘤病毒在制备治疗骨肉瘤的药物组合物中的应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
EP1141338A4 (fr) | 1998-12-31 | 2002-09-25 | Arch Dev Corp | Virus de l'herpes simplex recombinant utile dans le traitement des maladies neoplasiques |
AU2905199A (en) | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
DE60033530T2 (de) | 1999-08-24 | 2007-10-31 | Medarex Inc. | Humane antikörper gegen ctla-4 und deren verwendungen |
WO2001053505A2 (fr) | 2000-01-21 | 2001-07-26 | Biovex Limited | Souches de virus herpetique |
CN1286303A (zh) | 2000-08-17 | 2001-03-07 | 上海市农业科学院生物技术研究中心 | 抗人龋齿致病菌蛋白基因及其制备方法 |
US7749745B2 (en) | 2001-03-27 | 2010-07-06 | Georgetown University | Viral vectors and their use in therapeutic methods |
EP1456652A4 (fr) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | Agents modulant l'activite de cellules immunes et procedes d'utilisation associes |
MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
WO2006002394A2 (fr) | 2004-06-24 | 2006-01-05 | New York University | Souches de virus d'herpes simplex oncolytique non virulent modifiees pour bloquer la reponse hote innee |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
CN101230335B (zh) | 2007-01-22 | 2010-08-11 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
CN101230334B (zh) | 2007-01-22 | 2011-06-01 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
EP2535354B1 (fr) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée PD-1 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
WO2010089411A2 (fr) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Anticorps pd-1 et anticorps pd-l1 et leurs utilisations |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
SI2753355T1 (sl) | 2011-09-08 | 2019-02-28 | New York University | Onkolitični virus herpesa simpleksa in njegove terapevtske uporabe |
ES2871910T3 (es) * | 2012-08-30 | 2021-11-02 | Amgen Inc | Un método para tratar el melanoma usando un virus de herpes simple y un inhibidor de puntos de control inmunitario |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
JP6843736B2 (ja) * | 2014-07-16 | 2021-03-17 | トランジェーヌTransgene | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
ES2861450T3 (es) * | 2015-07-20 | 2021-10-06 | Virttu Biologics Ltd | Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer |
CN109069561A (zh) * | 2016-01-11 | 2018-12-21 | 图恩斯通有限合伙公司 | 溶瘤病毒和检查点抑制剂组合疗法 |
JP7208492B2 (ja) * | 2016-03-10 | 2023-01-19 | シージー オンコロジー, インコーポレイテッド | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
EP3225253A1 (fr) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Traitement du cancer avec un virus oncolytique combiné avec un inhibiteur de point de contrôle |
-
2018
- 2018-03-14 CN CN201880017970.9A patent/CN110461346A/zh active Pending
- 2018-03-14 WO PCT/US2018/022442 patent/WO2018170133A1/fr unknown
- 2018-03-14 US US16/493,376 patent/US20200009204A1/en active Pending
- 2018-03-14 JP JP2019549569A patent/JP2020510050A/ja active Pending
- 2018-03-14 AU AU2018235944A patent/AU2018235944B2/en active Active
- 2018-03-14 MX MX2019010797A patent/MX2019010797A/es unknown
- 2018-03-14 MA MA051630A patent/MA51630A/fr unknown
- 2018-03-14 EP EP18716700.2A patent/EP3595690A1/fr active Pending
- 2018-03-14 CA CA3056392A patent/CA3056392A1/fr active Pending
-
2023
- 2023-04-14 JP JP2023066170A patent/JP2023089171A/ja active Pending
-
2024
- 2024-04-02 AU AU2024202086A patent/AU2024202086A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018235944A1 (en) | 2019-09-26 |
US20200009204A1 (en) | 2020-01-09 |
JP2020510050A (ja) | 2020-04-02 |
AU2024202086A1 (en) | 2024-04-18 |
MX2019010797A (es) | 2019-10-24 |
CA3056392A1 (fr) | 2018-09-20 |
JP2023089171A (ja) | 2023-06-27 |
AU2018235944B2 (en) | 2024-01-04 |
WO2018170133A1 (fr) | 2018-09-20 |
CN110461346A (zh) | 2019-11-15 |
EP3595690A1 (fr) | 2020-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51630A (fr) | Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancer | |
SI3570830T1 (sl) | Psilocibin in/ali psilocin v kombinaciji s kanabinoidi in/ali terpeni | |
CL2019000278A1 (es) | Agentes rnai para infección con virus de hepatitis b. | |
PH12017500692A1 (en) | Antibody molecules to pd-l1 and uses thereof | |
CO2017002170A2 (es) | Terapia de combinación para tratar un paramixovirus | |
MX2022001043A (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas. | |
PH12016501482A1 (en) | Antibody molecules to tim-3 and uses thereof | |
BR112017025828A2 (pt) | dispositivo de nó hospedeiro e métodos de uso com o mesmo. | |
BR112017022917A2 (pt) | dispositivo de acoplamento direcional e métodos de uso com o mesmo. | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
TR201901582T4 (tr) | Kapsid | |
MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
ECSP17073209A (es) | Composiciones y métodos para el tratamiento de la anemia | |
MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
EA201692541A1 (ru) | Вакцины против вируса гриппа и их применения | |
DK3768305T3 (da) | Modificerede, onkolytiske adenovira | |
CL2019001295A1 (es) | Emulsión ultra alta en sólidos y aplicación | |
BR112016023833A2 (pt) | compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c | |
WO2014152946A3 (fr) | Polypeptides pour le traitement et/ou la limitation d'une infection grippale | |
AR103119A1 (es) | Uso de elsiglutida para tratar mucositis gastrointestinal, incluyendo diarrea inducida por quimioterapia | |
PH12017550047B1 (en) | Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus | |
IT201600086161A1 (it) | Mezzo filtrante e uso del mezzo filtrante. | |
ITUA20161865A1 (it) | Uso di lentinano per il trattamento e la prevenzione di endometriosi. | |
IT201700050733A1 (it) | Complesso comprendente almeno un calcio fosfato ed almeno un virus. |